EPAS1 and pulmonary arterial hypertension: Taken together, these data demonstrate that targeting of HIF2α in BOECs derived from PAH patients, reduced aberrant HIF2α target genes expression and reduced the hyperproliferative endothelial phenotype and arginase-2 activity to near healthy controls.